Vell Biologics is led by an experienced leadership team with decades of combined expertise in building and scaling rare-disease and serious chronic-disease businesses across India and the Middle East.
Our strength lies in translating scientific innovation into meaningful patient access. Through deep capabilities in regulatory strategy, market access, medical affairs, commercialisation, institutional engagement, and patient-support programmes, we understand what it takes to bring specialised therapies to patients in complex and underserved markets.
With an asset-light, access-led commercial model, we collaborate with global innovators to address four critical healthcare gaps: Awareness, Accessibility, Availability, and Affordability.
Experienced leadership across rare diseases, diabetes, and specialty biologics
Established understanding of India and Middle Eastern healthcare markets
End-to-end capabilities—from regulatory strategy to sustainable commercialisation
Strong engagement with healthcare professionals, institutions, and patient communities
Flexible partnership models tailored to each product and market
Clear, measurable patient-impact goals across every therapeutic area we enter
At Vell Biologics, success is measured not only by the therapies we introduce, but by the number of patients we serve—meaningfully, consistently, and sustainably.
